Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab

References

• GabrielSEMichaudKEpidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Res Ther200911322919519924
   PubMed Web of Science ®Google Scholar
• PincusTKavanaughASokkaTBenefit/risk of therapies for rheumatoid arthritis: underestimation of the “side effects” or risks of RA leads to underestimation of the benefit/risk of therapiesClin Exp Rheumatol2004225 Suppl 35211
   Web of Science ®Google Scholar
• NamJLWinthropKLvan VollenhovenRFCurrent evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAAnn Rheum Dis201069697698620447957
   PubMed Web of Science ®Google Scholar
• AndersonJJWellsGVerhoevenACFelsonDTFactors predicting response to treatment in rheumatoid arthritis: the importance of disease durationArthritis Rheum200043222910643696
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCHallSComparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialLancet200837237538218635256
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum200654263716385520
   PubMed Web of Science ®Google Scholar
• Goekoop-RuitermanYPde Vries-BouwstraJKAllaartCFClinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trialArthritis Rheum2005523381339016258899
   PubMed Web of Science ®Google Scholar
• JamalSPatraKKeystoneECAdalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysisClin Rheumatol200928441341919067101
   PubMed Web of Science ®Google Scholar
• Gómez-ReinoJBiologic monotherapy as initial treatment in patients with early rheumatoid arthritisRheumatology (Oxford)201251Suppl 5v31v3722718925
   PubMed Web of Science ®Google Scholar
• KeystoneECHaraouiBBykerkVPRole of infliximab in the treatment of early rheumatoid arthritisClin Exp Rheumatol2003215 Suppl 31200202
   Web of Science ®Google Scholar
• YaziciYMcMorrisBJDarkowTRosenblattLCPatient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritisClin Exp Rheumatol20092790791320149304
   PubMed Web of Science ®Google Scholar
• AletahaDEberlGNellVPMacholdKPSmolenJSAttitudes to early rheumatoid arthritis: changing patterns. Results of a surveyAnn Rheum Dis200463101269127515361385
   PubMed Web of Science ®Google Scholar
• KleinBWijdenesJZhangXGJourdanMBoironJMBrochierJMurine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemiaBlood199178119812041715218
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaMSaldanhaJReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growthCancer Res19935348518568428365
   PubMed Web of Science ®Google Scholar
• BeckJTHsuSMWijdenesJBrief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibodyN Engl J Med19943306026058302342
   PubMed Web of Science ®Google Scholar
• SackUKinneRWMarxTHepptPBenderSEmmrichFInterleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritisRheumatol Int199313245518356390
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency [homepage on the internet]Tokyo, Japan Available from http://www.pmda.go.jp/english/service/pdf/drugs/actemra_apr2008_e.pdfAccessed September 30, 2013
   Google Scholar
• European Medicines Agency [homepage on the internet]London Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000955/WC500054888.pdf/Accessed September 30, 2013
   Google Scholar
• U.S. Food and Drug Administration [homepage on the internet]USA Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000TOC.cfmAccessed September 30, 2013
   Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis2007661162116717485422
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum20065492817282916947782
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis201069889619297346
   PubMed Web of Science ®Google Scholar
• JonesGThe AMBITION trial: tocilizumab monotherapy for rheumatoid arthritisExpert Rev Clin Immunol20106218919520402381
   PubMed Web of Science ®Google Scholar
• BurmesterGRigbyWVollenhovenRVTocilizumab in combination and monotherapy versus methotrexate in methotrexate-naive patients with early rheumatoid arthritis: clinical and radiographic outcomes from a randomised, placebo-controlled trialAnn Rheum Dis201372Suppl 363
   Google Scholar
• DurezPDepresseuxGToukapANRate of remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERA trialAnn Rheum Dis201372Suppl 3623
   Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet200822371(9617)98799718358926
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• KojimaTKanekoAHiranoYEarly aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practiceMod Rheumatol201222337037521931942
   PubMed Web of Science ®Google Scholar
• YabeYKojimaTKanekoAAsaiNKobayakawaTIshiguroNA review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) StudyMod Rheumatol201323224525322526833
   PubMed Web of Science ®Google Scholar
• FelsonDTSmolenJSWellsGAmerican College of Rheumatology; European League Against RheumatismAmerican College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsArthritis Rheum20116357358621294106
   PubMed Web of Science ®Google Scholar
• HoussiauFADevogelaerJPvan DammeJde DeuxchaisnesCNVan SnickJInterleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritidesArthritis Rheum1988317847883260102
   PubMed Web of Science ®Google Scholar
• NakaharaHSongJSugimotoMAnti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritisArthritis Rheum2003481521152912794819
   PubMed Web of Science ®Google Scholar
• KayakabeKKuroiwaTSakuraiNInterleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritisRheumatology (Oxford)20125191571157922596210
   PubMed Web of Science ®Google Scholar
• FiresteinGSStarving the synovium: angiogenesis and inflammation in rheumatoid arthritisJ Clin Invest1999103349884327
   PubMed Web of Science ®Google Scholar
• PalmqvistPPerssonEConawayHHLernerUHIL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariaeJ Immunol200216963353336212218157
   PubMed Web of Science ®Google Scholar
• KarsdalMASchettGEmeryPIL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522)Semin Arthritis Rheum201242213113922397953
   PubMed Web of Science ®Google Scholar